Everyone Wins In Deal Between BMS And The Medicines Co.
This article was originally published in The Pink Sheet Daily
Executive Summary
Bristol-Myers Squibb has agreed to license its already-marketed topical hemostat to The Medicines Company for $115 million upfront and royalties. The agreement will last for two years and add to The Medicines Co.'s portfolio of perioperative care products.